Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)

BACKGROUND: Despite available interventions, people with type 2 diabetes (T2D) remain at risk of chronic kidney disease (CKD). Finerenone, a potent and selective nonsteroidal mineralocorticoid receptor antagonist, and sodium–glucose cotransporter 2 inhibitors (SGLT2is) can reduce both kidney and car...

Descripción completa

Detalles Bibliográficos
Autores principales: Green, Jennifer B, Mottl, Amy K, Bakris, George, Heerspink, Hiddo J L, Mann, Johannes F E, McGill, Janet B, Nangaku, Masaomi, Rossing, Peter, Scott, Charlie, Gay, Alain, Agarwal, Rajiv
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064838/
https://www.ncbi.nlm.nih.gov/pubmed/35700142
http://dx.doi.org/10.1093/ndt/gfac198

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064838/
https://www.ncbi.nlm.nih.gov/pubmed/35700142
http://dx.doi.org/10.1093/ndt/gfac198

Ejemplares similares